Notification That Annual Report Will Be Submitted Late (nt 10-k)
March 31 2023 - 12:03PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
12b-25
SEC
File Number 000-54933
CUSIP
Number 45252A107
NOTIFICATION
OF LATE FILING
(Check
One): |
☒
Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q |
|
☐
Form 10-D ☐ Form N-CEN ☐ Form N-CSR |
|
For
Period Ended: December 31, 2022 |
|
|
|
☐
Transition Report on Form 10-K |
|
|
|
☐
Transition Report on Form 20-F |
|
|
|
☐
Transition Report on Form 11-K |
|
|
|
☐
Transition Report on Form 10-Q |
|
For
the Transition Period Ended: |
|
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I – REGISTRANT INFORMATION
IMMUNE
THERAPEUTICS, INC.
Full
Name of Registrant
2431
Aloma Ave., Suite 124
Address
of Principal Executive Office (Street and Number)
Winter
Park, FL 32792
City,
State and Zip Code
PART
II – RULE 12-b 25 (b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate.)
|
(a) |
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
|
|
|
☒ |
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-CEN or Form N-CSR, or portion thereof,
will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition
report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar
day following the prescribed due date; and |
|
|
|
|
(c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III – NARRATIVE
State
below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period. (Attach extra sheets if needed.)
The
registrant has not finalized its financial statements for the fiscal year ended December 31, 2022. As a result, the registrant is unable
to file its Annual Report on Form 10-K within the prescribed time period without unreasonable effort or expense. The registrant anticipates
that it will file Form 10-K within the fifteen-day grace period provided by Exchange Act Rule 12b-25.
PART
IV – OTHER INFORMATION
(1) |
Name
and telephone number of person to contact in regard to this notification |
|
Kelly
Wilson |
|
(888) |
|
613-8802 |
|
(Name) |
|
(Area
Code) |
|
(Telephone
Number) |
(2) |
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s). |
|
|
|
☒
Yes ☐ No |
|
|
|
|
(3) |
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof? |
|
|
|
☐
Yes ☒ No |
If
so, attach an explanation of the anticipated change, both narratively and quantitatively,
and, if appropriate, state the reasons why a reasonable estimate of the results cannot be
made.
IMMUNE
THERAPEUTICS, INC.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: |
March
31, 2023 |
|
By: |
/s/
Kelly Wilson |
|
|
|
|
Kelly
Wilson |
|
|
|
|
Interim
Chief Executive Officer |
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Aug 2023 to Aug 2024